BC
GILD icon

Bridgefront Capital’s Gilead Sciences GILD Stock Holding History

Bridgefront Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,924
Closed -$435K – 672
2025
Q2 		$435K Buy
+3,924
New +$418K 0.12% 308
2024
Q2 		– Sell
-9,424
Closed -$690K – 552
2024
Q1 		$690K Buy
+9,424
New +$725K 0.52% 32
2023
Q3 		– Sell
-5,890
Closed -$454K – 471
2023
Q2 		$454K Buy
+5,890
New +$470K 0.25% 136
2022
Q3 		– Sell
-3,564
Closed -$220K – 372
2022
Q2 		$220K Buy
+3,564
New +$221K 0.24% 207
2021
Q3 		– Sell
-4,039
Closed -$278K – 472
2021
Q2 		$278K Buy
+4,039
New +$270K 0.1% 376

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bridgefront Capital's GILD Position: Q3 2025 in Review

Bridgefront Capital sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 3,924 shares — an estimated $435K sold.

Bridgefront Capital first reported a position in GILD in Q2 2021 and held it in 5 quarters. The position peaked at $690K in Q1 2024. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

  • Bridgefront Capital reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
  • Bridgefront Capital sold 3,924 Gilead Sciences shares in Q3 2025, an estimated $435K.
  • Bridgefront Capital first reported a position in Gilead Sciences in Q2 2021 and held it in 5 quarters.
  • Bridgefront Capital's Gilead Sciences position peaked at $690K in Q1 2024.
  • 2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on Bridgefront Capital's 13F filing for Q3 2025, filed 14 Nov 2025.